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Uterine leiomyomata (fibroids) are benign 
smooth-muscle tumors, which are associated 
with pelvic pain, heavy bleeding, and repro-
ductive problems (Stewart 2001), and this 
accounts for their being the most common 
indication for hysterectomies in the United 
States (Farquhar and Steiner 2002). The 
National Institute of Environmental Health 
Sciences (NIEHS) Uterine Fibroid Study, 
which used ultrasound screening to detect 
fibroids in participants, estimated that the 
risk of fibroids by 50 years of age exceeds 
80% among African Americans and is 
nearly 70% among Caucasians (Baird et al. 
2003). However, prevalence estimates based 
on clinically evident diagnoses have been 
approximately 25% (Stewart 2001). Age in 
premenopausal women and African-American 
race/ethnicity have been the most consis-
tently reported risk factors (Baird et al. 2003; 
Faerstein et al. 2001; Marshall et al. 1997).
Both estrogen and progesterone have been 
implicated in fibroid pathogenesis, although 
the mechanisms by which these hormones act 
have not been elucidated (Marsh and Bulun 
2006). Early-life and childhood exposures 
can affect uterine development and women’s 
response to estrogen or progesterone later 
in life and thus may influence fibroid devel-
opment (Baird 2004). For instance, infants 
fed with soy formula are exposed to higher 
levels per unit body weight of estrogenic 
isoflavones than are adults consuming soy-
based foods (Setchell et al. 1997). Although 
data in humans on long-term outcomes are 
limited, one small study has shown greater 
side effects of menstruation among women 
fed soy formula (Strom et al. 2001). Other 
early-life and childhood exposures also have 
not been previously investigated in relation 
to fibroids, except for in utero diethylstilbe-
strol (DES) (Baird and Newbold 2005; Wise 
et al. 2005a), age at menarche (Marshall et al. 
1998; Wise et al. 2004), and childhood obe-
sity (Terry et al. 2007).
We examined whether in utero, early-life, 
and childhood exposures were associated with 
self-report of fibroid diagnosis by 35 years 
of age among non-Hispanic white partici-
pants in the NIEHS Sister Study. Specifically, 
we evaluated the following participant fac-
tors: birth weight, gestational age at birth, 
birth order, being from a singleton or mul-
tiple birth, breast milk or soy formula con-
sumption during infancy, relative height and 
weight during childhood, age at menarche; 
and the following childhood socioeconomic 
factors: maternal education, highest level of 
education in the household, food insecurity, 
and relative family income. In addition, we 
evaluated maternal factors related to the preg-
nancy with the participant: age at birth, living 
and working on a farm, smoking during preg-
nancy, prepregnancy diabetes, DES use, and 
complications of pregnancy (preeclampsia, 
pregnancy-related hypertension, and gesta-
tional diabetes).
Materials and Methods
Study population. The NIEHS Sister Study 
(NIEHS 2010) is a prospective cohort study 
that evaluates environmental and genetic risk 
factors for breast cancer and other end points 
in approximately 50,000 U.S. and Puerto 
Rican volunteer women 35–74 years of age. 
Eligibility criteria also included no previous 
diagnosis of breast cancer and a full or half-
sister who was diagnosed with breast cancer. 
Study materials were available in English and 
Spanish. Recruitment for the Sister Study 
began in August 2003 with a vanguard group 
of women from four U.S. cities. The Sister 
Study opened nationally in October 2004 
and closed in March 2009. Of 62,812 eligible 
women who agreed to enroll, 50,884 com-
pleted all baseline enrollment activities (fully 
enrolled) by 31 July 2009. The geographic 
distribution of participants for U.S. census 
regions and Puerto Rico is approximately 22% 
(West), 27% (Midwest), 17% (Northeast), 
33% (South), and 2% (Puerto Rico).
Participants were mailed kits containing 
three questionnaires for self-completion (diet, 
family history, and use of personal care prod-
ucts), written consent documents, and sup-
port information for telephone interviews 
and home visits. A prepaid phone card was 
included to encourage participants to contact 
their mother or other relatives about early-
life events and family medical history. Home 
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Ba c k g r o u n d: Early-life exposures to hormonally active compounds and other factors may affect 
later response to estrogen or progesterone and hence may influence development of uterine leio-
myomata (fibroids).
oBjectives: We evaluated associations of in utero and early-life exposures, including soy formula, 
with self-report of physician-diagnosed fibroids by 35 years of age.
Me t h o d s : Our study included 19,972 non-Hispanic white women who were 35–59 years of age 
when they enrolled in the Sister Study in 2003–2007. We estimated risk ratios (RRs) and 95% con-
fidence intervals (CIs) using log-binomial regression models for fibroid associations with adjustment 
for participant’s age and education, maternal age at participant’s birth, birth order, and childhood 
family income.
re s u l t s: Greater risk of early fibroid diagnosis was associated with soy formula during infancy (RR 
= 1.25; 95% CI, 0.97–1.61), maternal prepregnancy diabetes (RR = 2.05; 95% CI, 1.16–3.63), low 
childhood socioeconomic status (RR = 1.28; 95% CI, 1.01–1.63), and gestational age at birth (RR 
= 1.64; 95% CI, 1.27–2.13, for being born at least 1 month early). In utero diethylstilbestrol (DES) 
exposure was also associated with early fibroid diagnosis (RR = 1.42; 95% CI, 1.13–1.80), but this 
association was driven by women reporting probable rather than definite exposure.
co n c l u s i o n s: There are plausible biological pathways by which these early-life factors could pro-
mote fibroid pathogenesis. This is the first epidemiologic study to evaluate such exposures, with the 
exception of in utero DES, in relation to fibroid risk, and replication of findings in other popula-
tions is needed.
key w o r d s : diabetes mellitus, diethylstilbestrol, early life, leiomyoma, phytoestrogens, preg-
nancy, prenatal exposure delayed effects, socioeconomic factors, soy formula. Environ Health 
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visits included measurement of participants’ 
height and weight and retrieval of completed 
questionnaires. Participants completed a 
computer-assisted telephone interview to col-
lect information on known and suspected 
risk factors for breast cancer and other end 
points. The Sister Study was approved by the 
Institutional Review Board of the NIEHS, 
National Institutes of Health, and all partici-
pants provided their informed consent.
Baseline data were available for 32,071 
women who completed their interview 
and home visit by 21 September 2007. 
We restricted our analysis to 20,061 non-
  Hispanic whites who were 35–59 years of age 
when fully enrolled into the Sister Study. We 
excluded women > 59 years of age because 
of the likelihood of secular differences in 
use of ultrasounds for fibroid diagnoses and 
decreased ability to get information from 
their mothers about early-life events. Because 
of racial/ethnic differences in fibroid risk and 
related morbidity (Baird et al. 2003; Faerstein 
et al. 2001; Marshall et al. 1997; Wise et al. 
2005b), we restricted our study population to 
non-Hispanic whites because we did not have 
sufficient numbers to separately evaluate other 
races/ethnicities at the time of our analysis. 
The present analysis includes 19,972 women 
after excluding 43 women who were missing 
data on fibroid status, 40 with missing age 
at diagnosis, and 6 who reported childhood 
or adolescent ages at diagnosis (< 15 years). 
Although the Sister Study is a prospective 
cohort study, our analysis is based on retro-
spectively collected information on factors 
that occurred before the diagnosis of fibroids.
Fibroid assessment. During the baseline 
interview, women reported whether they were 
ever told by a doctor or health professional that 
they had uterine fibroids and their age at time 
of diagnosis. Because ultrasound screening has 
shown that the prevalence of fibroids increases 
rapidly after 35 years of age in U.S. white 
women (Baird et al. 2003), many older women 
will have undiagnosed fibroids. Therefore, we 
limited our case group to those who reported 
a fibroid diagnosis by 35 years of age to reduce 
disease misclassification in noncases.
Exposure and covariate assessment. We 
used self-administered family history ques-
tionnaires to assess most intrauterine and 
early-life exposures: birth weight (pounds/
ounces), gestational age at birth (categories), 
singleton or multiple birth, breast milk or soy 
formula consumption during infancy; and 
maternal exposures: age at birth, living and 
working on a farm, smoking during preg-
nancy, prepregnancy diabetes, DES use, and 
complications of pregnancy (preeclampsia, 
pregnancy-related hypertension, and ges-
tational diabetes). Except for questions on 
gestational age, birth weight, singleton or 
multiple birth, and maternal age at birth, the 
response categories were “definitely,” “prob-
ably,” “probably not,” and “definitely not” to 
allow for possible uncertainty about early-life 
events. Questionnaires also assessed the dura-
tion that participants were fed with breast 
milk or soy formula and whether they were 
fed with soy formula during the first 2 months 
of life. However, we did not evaluate duration 
of breast-feeding or soy formula in relation 
to fibroids because of a considerable propor-
tion of missing responses among women who 
reported being breast-fed (> 20%) or fed soy 
formula (> 30%). For analyses, we did not 
consider mothers as having gestational dia-
betes if they were reported to have diabetes 
before pregnancy. If participants reported 
that their mothers had both preeclampsia and 
pregnancy-related hypertension, we consid-
ered their mothers as having preeclampsia in 
analyses, and we considered mothers as hav-
ing pregnancy-related hypertension only if 
preeclampsia was not also reported.
Birth order was estimated from birth dates 
of brothers reported on the family history 
questionnaires and sisters reported during the 
computer-assisted telephone interviews. We 
included all full siblings and half-siblings who 
shared the same mother for defining birth 
order. Childhood exposure data—maternal 
education and maximum level of education 
for parents or guardian in the household 
when participant was 13 years of age, relative 
family income based on self-reported cate-
gories (poor, low, middle, or well off), not 
enough to eat at times during childhood, age 
at menarche, and height and weight relative 
to peers at age 10—were collected during the 
telephone interview. Participant’s age, highest 
level of education, smoking status, alcohol 
intake, parity, and menopausal status were 
also assessed during the telephone interview, 
and body mass index was calculated using 
weight and height measured at the home visit.
Statistical analyses. All statistical analy-
ses were conducted using SAS (version 9.1; 
SAS Institute Inc., Cary, NC). We used log-
binomial regression to estimate risk ratios 
(RRs) with 95% confidence intervals (CIs) 
for associations between each of the intra-
uterine, early-life, and childhood exposures 
and fibroid diagnosis by 35 years of age. For 
each of the relevant exposures, we combined 
women who reported definite or probable 
exposure for estimation of RRs and con-
sidered women unexposed if they reported 
probably not or definitely not. We later per-
formed sensitivity analyses in which we esti-
mated associations separately for women who 
reported definite exposure and those who 
reported probable exposure. We estimated 
associations with fibroids within the following 
categories of birth weight: < 2,500 g, 2,500–
2,999 g, 3,000–3,499 g, 3,500–3,999 g, 
and ≥ 4,000 g. For maternal age, we initially 
examined associations with 5-year age catego-
ries and then further combined categories that 
were associated with a similar risk of fibroids. 
Likewise, we initially explored fibroid asso-
ciations across all categories of birth order 
and maternal and household education, and 
then combined categories with similar fibroid 
risk for reporting of associations. Although 
approximately 40% of women did not report 
gestational age at birth, we evaluated its asso-
ciation with fibroids, categorizing women 
as having been born at least 1 month early, 
2–4 weeks early, and not early (< 2 weeks 
before due date, on time, or late). Birth 
weight analyses were repeated with exclusion 
of women who reported being born at least 
1 month early to further our understanding 
of birth weight and gestational age associa-
tions. We estimated RRs that were adjusted 
for participant factors (participant’s age 
and education) that may affect reporting of 
fibroids and exposures. We also adjusted RRs 
for early-life factors (birth order, maternal 
age at birth, and family income) that may be 
associated with other exposures and fibroids 
but were not considered to be on the causal 
pathway. The sample sizes for age-adjusted 
and fully adjusted models shown in tables dif-
fer. Although these differences are only about 
2%, we repeated the age-adjusted analyses for 
the 19,531 women with complete data on 
variables included in the fully adjusted models 
and verified that results were similar to those 
for the complete sample of 19,972 women 
(data not shown).
Results
The prevalence of self-reported fibroids diag-
nosed at any age was 25% (data not shown), 
with 8% of women reporting early diagnosis 
by 35 years of age (Table 1). Women report-
ing early diagnosis of fibroids (cases) were 
slightly less likely than women without early 
diagnosis (noncases) to be younger (35–44 
years, 16% vs. 20%) or to have a bachelor’s or 
graduate degree (53% vs. 57%). As expected, 
cases were more likely than noncases to report 
being surgically menopausal at enrollment 
(48% vs. 21%). We also found that a greater 
proportion of cases reported having a hyster-
ectomy by 35 years of age than noncases (21% 
vs. 5%) (data not shown). We had expected 
a greater proportion of cases than noncases 
to have been nulliparous at 35 years of age, 
but proportions were similar (25% vs. 26%). 
However, as suggested by Baird and Dunson 
(2003), we further restricted our evaluation 
of live or still births to those that occurred 
between 25 and 35 years of age and found 
that cases were more likely to report having no 
live or still births during these ages than were 
noncases (45% vs. 39%) (data not shown).
Early-life factors. Five of the 14 early-life 
factors we examined were associated with more Early-life exposures and uterine fibroids
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than a 20% increase in risk of early fibroid 
diagnosis (DES, prepregnancy diabetes, ges-
tational diabetes, soy formula, and gestational 
age at birth) (Table 2). We noted the strongest 
association with fibroids for maternal diabetes 
before pregnancy (fully adjusted RR = 2.05; 
95% CI, 1.16–3.63). We found an increased 
risk of fibroids in association with being fed 
soy formula within the first 2 months of life 
(adjusted RR = 1.25; 95% CI, 0.90–1.73), 
which was similar to that for any soy formula 
use (adjusted RR = 1.25; 95% CI, 0.97–1.61). 
Although only 60% of women reported ges-
tational age at birth, we found a strong asso-
ciation with being born at least 1 month early 
(adjusted RR = 1.64; 95% CI, 1.27–2.13). 
Weak associations of at least a 10% increase 
in risk of fibroids were also noted for being 
firstborn, low birth weight (< 2,500 g), and 
reporting maternal pregnancy-related hyper-
tension or preeclampsia. However, when we 
excluded women who reported being born 
at least 1 month early, there was no associa-
tion with low birth weight (adjusted RR = 
0.99; 95% CI, 0.79–1.25). Maternal age at 
participant’s birth also was weakly associated 
with increased fibroid risk. However, when we 
excluded firstborn women from analyses, the 
risk of fibroids was no longer elevated for hav-
ing younger mothers (< 20 years), although 
the association for having older mothers (≥ 40 
years) remained (data not shown). Having a 
mother who worked and lived on a farm or 
smoked during her pregnancy, being from 
a multiple birth, and having been breast-fed 
were not associated with fibroids.
Overall, the age-adjusted and fully 
adjusted RR estimates for the 14 evaluated 
exposures were similar, although the asso-
ciation between young maternal age (< 20 
years) and fibroids was attenuated in the fully 
adjusted model. After repeating our analyses 
by estimating fibroid associations separately 
for women who reported “definitely” and 
those who reported “probably” for relevant 
early-life exposures, reporting of probable 
in utero exposure to DES (fully adjusted RR 
= 2.07; 95% CI, 1.53–2.80) and gestational 
diabetes (fully adjusted RR = 1.88; 95% CI, 
0.94–3.74) were associated with fibroids, 
but there were no associations with definite 
in utero exposure to DES and gestational dia-
betes (Table 3).
Childhood factors. Childhood socioeco-
nomic factors, including less than high school 
for highest level of household education, not 
enough to eat at times during childhood, and 
being poor in childhood, were associated with 
fibroids, with the strongest association for 
being poor (RR = 1.24; 95% CI, 0.99–1.55) 
(Table 4). Because these socioeconomic fac-
tors are correlated, we evaluated whether 
fibroid associations were stronger with having 
multiple factors indicating low socioeconomic 
status. Having two or three of these child-
hood socioeconomic factors resulted in a 
slightly stronger association with fibroids (RR 
= 1.28; 95% CI, 1.01–1.63) than having only 
one of these factors (RR = 1.17; 95% CI, 
1.01–1.35). As expected from previous stud-
ies (Marshall et al. 1998; Wise et al. 2004), 
earlier age at menarche was associated with 
greater risk of early fibroid diagnosis. Taller 
height and heavier weight at 10 years of age 
relative to peers were only weakly associated 
with fibroids.
Discussion
We estimated an increased risk of early fibroid 
diagnosis in association with being fed soy 
formula during infancy, having a mother with 
prepregnancy diabetes, being born at least 
1 month early, and reporting factors indicat-
ing low socioeconomic status during child-
hood (low household education, being poor, 
and not having enough to eat). We also noted 
associations with fibroids for having a mother 
with gestational diabetes and DES use during 
pregnancy, although these associations were 
restricted to reporting probable rather than 
definite exposure.
The association with soy formula is of 
interest given the estrogenic isoflavones found 
in soy products. Infants fed soy formula are 
exposed to isoflavone levels that are more 
than five times higher than typical levels for 
adults consuming soy-based foods (Setchell 
et al. 1997). Genistin is the naturally occur-
ring isoflavone predominantly contained in 
soy formula, which can easily be hydrolyzed 
in the gut to the estrogenically active form of 
the compound, genistein, based on report-
ing of high plasma (Setchell et al. 1997) and 
urinary (Cao et al. 2009; Hoey et al. 2004) 
concentrations of genistein in infants fed soy 
formula. The increased risk of fibroids in asso-
ciation with being fed soy formula within the 
first 2 months of life, which may include the 
time period most sensitive to genistein expo-
sure, was similar to the association with soy 
formula at any time during infancy.
Genistein has been extensively inves-
tigated in laboratory animals. In particular, 
neo  natal treatment of mice with genistein has 
been associated with development of uterine 
adeno    carcinoma (Newbold et al. 2001), abnor-
malities with mammary gland development 
and differences with mammary gland levels of 
Table 1. Participant characteristics [n (%)] by uterine fibroids status of non-Hispanic whites, 35–59 years 
of age, in the Sister Study, 2003–2007 (n = 19,972).a
Characteristic Cases Noncases
Total 1,526 18,446
Age (years)
35–44 241 (15.8) 3,712 (20.1)
45–59 1,285 (84.2) 14,734 (79.9)
Highest level of educationb
High school or lessc 201 (13.2) 2,159 (11.7)
Some college/vocational school 519 (34.0) 5,809 (31.5)
Bachelor’s degree 403 (26.4) 5,706 (30.9)
Graduate degree 403 (26.4) 4,771 (25.9)
Smoking statusb
Current 195 (12.8) 2,105 (11.4)
Former 496 (32.5) 6,125 (33.2)
Never 835 (54.7) 10,213 (55.4)
Alcohol intake (drinks per week)b
0 242 (15.9) 2,529 (13.7)
0.01–0.49 446 (29.3) 5,189 (28.2)
0.50–2.00 341 (22.4) 4,257 (23.1)
2.01–6.99 305 (20.0) 3,821 (20.7)
≥ 7.00 190 (12.5) 2,637 (14.3)
Body mass indexb
< 25 614 (40.4) 8,217 (44.8)
25–29.9 479 (31.5) 5,421 (29.5)
≥ 30 428 (28.1) 4,720 (25.7)
Parityb,d
0 381 (25.0) 4,883 (26.5)
1 297 (19.5) 3,049 (16.5)
2 553 (36.3) 6,751 (36.6)
≥ 3 293 (19.2) 3,754 (20.4)
Menopausal statusb
Premenopausal 449 (29.4) 8,733 (47.4)
Natural 346 (22.7) 5,793 (31.4)
Surgicale 731 (47.9) 3,914 (21.2)
aCases were self-reported diagnosis of fibroids at ≤ 35 years of age, excluding 89 women missing fibroid status or age 
at diagnosis or who reported childhood or adolescent ages at diagnosis (< 15 years). bNumber does not sum to total 
because of missing data. cLess than high school: fibroids (n = 13), no fibroids (n = 79). dTotal number of live and still 
births by 35 years of age. eIncludes women with hysterectomy or endometrial ablation in which actual timing of hor-
monal transition is unknown.D’Aloisio et al.
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estrogen and progesterone receptors (Padilla-
Banks et al. 2006), alterations with estrous 
cycles and reduced fertility (Jefferson et al. 
2005, 2007), and early reproductive senescence 
(Jefferson et al. 2005). However, studies with 
adult outcomes in humans have been lacking, 
except for one small study reporting longer 
duration and increased pain with menstrual 
bleeding for women who were fed soy formula 
(Strom et al. 2001). This finding is interesting 
given that pelvic pain and heavy bleeding are 
the most common symptoms of fibroids.
Our strongest association with fibroids 
was for maternal prepregnancy diabetes. 
Prenatal exposure to diabetes has also been 
associated with increased risk of obesity, 
abnormal glucose tolerance, and type 2 dia-
betes in adulthood (Dabelea 2007; Fetita 
Table 2. RRs for associations of uterine fibroids with in utero and early-life exposures among non-Hispanic whites, 35–59 years of age, in the Sister Study, 
2003–2007.a
Age adjusted (n = 19,972)b Fully adjusted (n = 19,531)b
Exposure n No. of cases RR 95% CI n No. of cases RR 95% CI
Maternal pregnancy factors
Worked and lived on farmc,d
Yes 1,611 134 1.08 0.91–1.28 1,588 132 1.02 0.86–1.22
Noe 16,823 1,275 1.00 16,639 1,262 1.00
Smokingc,d
Yes 6,987 533 1.01 0.91–1.12 6,893 529 1.02 0.92–1.13
No 12,142 916 1.00 12,025 905 1.00
DES usec,d
Yes 658 69 1.40 1.11–1.76 643 68 1.42 1.13–1.80
No 16,723 1,234 1.00 16,563 1,224 1.00
Prepregnancy diabetesc,d
Yes 64 10 2.08 1.18–3.69 64 10 2.05 1.16–3.63
No 19,541 1,484 1.00 19,329 1,468 1.00
Gestational diabetesc,d
Yesf 101 9 1.25 0.67–2.34 101 9 1.28 0.68–2.38
No 18,283 1,373 1.00 18,101 1,359 1.00
Preeclampsia/eclampsiac,d
Yes 394 37 1.26 0.92–1.71 390 36 1.20 0.87–1.64
No 17,247 1,283 1.00 17,077 1,270 1.00
Pregnancy-related hypertensionc,d
Yesg 243 20 1.11 0.73–1.70 243 20 1.12 0.73–1.71
No 16,459 1,238 1.00 16,299 1,226 1.00
Maternal age at birth (years)c
< 20 688 68 1.31 1.04–1.66 676 67 1.19 0.92–1.53
20–24 4,334 345 1.06 0.94–1.20 4,310 342 1.01 0.89–1.15
25–34 10,801 806 1.00 10,764 803 1.00
35–39 2,787 195 0.95 0.82–1.11 2,780 195 0.96 0.82–1.11
≥ 40 1,003 83 1.14 0.91–1.41 1,001 83 1.14 0.92–1.42
Participant factors
Firstbornc
Yes 3,850 326 1.12 0.99–1.25 3,834 326 1.11 0.97–1.27
No 15,842 1,173 1.00 15,697 1,164 1.00
Birth weight (g)c
< 2,500 1,382 120 1.13 0.93–1.37 1,361 118 1.12 0.92–1.36
2,500–2,999 3,086 244 1.04 0.90–1.21 3,050 242 1.04 0.89–1.20
3,000–3,499 6,191 471 1.00 6,141 466 1.00
3,500–3,999 3,928 281 0.94 0.82–1.09 3,897 278 0.94 0.82–1.09
≥ 4,000 1,364 108 1.05 0.86–1.28 1,354 107 1.05 0.86–1.29
Gestational age at birthc
Born ≥ 1 month early 464 54 1.63 1.26–2.11 459 54 1.64 1.27–2.13
Born 2–4 weeks early 1,017 77 1.08 0.86–1.35 1,010 76 1.08 0.86–1.36
Not born ≥ 2 weeks early 10,129 716 1.00 10,031 706 1.00
Multiple birthc
Yes 692 49 0.93 0.71–1.22 679 48 0.93 0.70–1.22
No 19,037 1,454 1.00 18,825 1,439 1.00
Fed breast milkc,d
Ever 7,240 538 0.95 0.86–1.05 7,167 526 0.93 0.84–1.03
None 11,543 890 1.00 11,421 887 1.00
Fed soy formulac,d
Ever 645 60 1.28 1.00–1.64 641 58 1.25 0.97–1.61
None 16,180 1,212 1.00 16,012 1,201 1.00
Fed soy formula, age ≤ 2 monthsc
Yes 386 34 1.22 0.88–1.69 384 34 1.25 0.90–1.73
No 16,387 1,226 1.00 16,215 1,215 1.00
aFibroids status based on self-reported diagnosis at ≤ 35 years of age, excluding 89 women missing fibroid status or age at diagnosis or who reported childhood or adolescent ages 
at diagnosis (< 15 years). bEach age-adjusted model included participant’s age; each fully adjusted model included the following covariates: participant’s age and education, maternal 
age, firstborn status, and childhood family income. cn does not sum to total because of missing data. Percent with missing data was as high as 20%, with the exception of 40% with 
missing gestational age at birth. dYes or ever represents reporting of definitely or probably. No or none represents reporting of probably not or definitely not. eExcludes those reporting 
mothers who worked or lived on a farm during pregnancy (age adjusted, n = 956; fully adjusted, n = 949). fExcludes those reporting mothers who definitely or probably had diabetes 
before pregnancy. gExcludes those reporting mothers who definitely or probably had preeclampsia during pregnancy.Early-life exposures and uterine fibroids
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et al. 2006). However, this is the first study to 
evaluate whether in utero exposure to mater-
nal diabetes affects fibroid risk in early adult-
hood. One hypothetical mechanism by which 
in utero exposure to diabetes would affect 
later fibroid pathogenesis is the alteration of 
methylation patterns in regions that affect 
expression of relevant genes. In particular, 
expression of imprinted genes is especially 
sensitive to changes in methylation patterns 
(Thompson et al. 2001; Waterland and Jirtle 
2004). Two studies in mice have reported 
that exposure of fetuses to induced maternal 
diabetes and of embryos before implanta-
tion to in vitro insulin affected expression of 
two imprinted neighboring genes, H19 and 
IGF2, by altering their methylation status and 
resulted in changes in fetal development and 
birth weight (Shao et al. 2007, 2008). Seven 
microarray studies reviewed by Arslan et al. 
(2005) reported at least a 2-fold increase in 
IGF2 expression in fibroids relative to normal 
myometrium.
Using the animal model of fibroids, the 
Eker rat, Cook et al. (2007) found an asso-
ciation between early exposure to DES and 
later fibroid development. Consistent with 
the animal model, Baird and Newbold (2005) 
reported a positive association of self-reported 
in utero DES exposure with fibroid diagnosis 
based on ultrasound assessment within the 
NIEHS Uterine Fibroid Study. However, 
Wise et al. (2005a) reported no association 
between maternal DES use and fibroids based 
on medically documented DES exposure and 
surgical fibroid cases. Given our inconsistent 
associations for women who report definite 
versus probable in utero DES exposure, con-
clusions from our study are unclear.
Table 3. RRs considering certainty of in utero and early-life exposures in uterine fibroid associations among non-Hispanic whites, 35–59 years of age, in the 
Sister Study, 2003–2007.a
Definite Probable
Exposure n No. of cases aRRb 95% CI n No. of cases aRRb 95% CI
Worked and lived on farmc 970 80 1.02 0.82–1.27 618 52 1.04 0.79–1.35
Smoking during pregnancy 5,040 368 0.97 0.87–1.10 1,853 161 1.14 0.97–1.34
DES use 404 31 1.04 0.74–1.46 239 37 2.07 1.53–2.80
Prepregnancy diabetes 29 5 2.26 1.02–5.01 35 5 1.88 0.83–4.23
Gestational diabetesd 50 2 0.60 0.15–2.33 51 7 1.88 0.94–3.74
Preeclampsia/eclampsia 248 22 1.15 0.77–1.72 142 14 1.28 0.78–2.11
Pregnancy-related hypertensione 115 11 1.30 0.74–2.28 128 9 0.96 0.51–1.80
Fed breast milk 6,356 462 0.92 0.83–1.03 811 64 0.99 0.77–1.26
Fed soy formula 481 46 1.32 1.00–1.75 160 12 1.03 0.60–1.78
aRR, adjusted risk ratio. 
aFibroids status based on self-report of diagnosis at ≤ 35 years of age, excluding 89 women missing fibroid status or age at diagnosis or who reported childhood or adolescent ages at 
diagnosis (< 15 years). bEach model included the following covariates: participant’s age and education, maternal age, firstborn status, and childhood family income (n = 19,531). The ref-
erence group is women who reported probably not or definitely not for each exposure. cExcludes from the reference group those reporting mothers who worked or lived on a farm (but 
not both) during pregnancy (n = 949). dExcludes those reporting mothers who definitely or probably had diabetes before pregnancy. eExcludes those reporting mothers who definitely or 
probably had preeclampsia during pregnancy.
Table 4. RRs for associations of uterine fibroids with childhood socioeconomic and developmental factors among non-Hispanic whites, 35–59 years of age, in 
the Sister Study, 2003–2007.a
Age adjusted (n = 19,972)b Fully adjusted (n = 19,531)b
Exposure n No. of cases RR 95% CI n No. of cases RR 95% CI
Maternal education at participant age 13c
< High school 2,988 250 1.10 0.96–1.25 2,925 246 1.05 0.91–1.21
≥ High school 16,339 1,220 1.00 15,986 1,188 1.00
Maximum household education at participant age 13c
< High school 1,876 173 1.21 1.04–1.41 1,833 171 1.15 0.98–1.36
≥ High school 18,007 1,347 1.00 17,618 1,313 1.00
Family incomec
Poor 819 77 1.24 1.00–1.55 793 76 1.24 0.99–1.55
Low 4,279 345 1.07 0.95–1.20 4,192 342 1.07 0.95–1.21
Middle/well off 14,859 1,104 1.00 14,546 1,072 1.00
Not enough to eatc
Yes 1,400 129 1.22 1.02–1.44 1,346 128 1.16 0.96–1.40
No 18,567 1,396 1.00 18,180 1,361 1.00
Age at menarche (years)c
< 10 1,106 120 1.54 1.27–1.87 1,076 117 1.54 1.26–1.87
11 2,565 242 1.35 1.16–1.57 2,511 232 1.32 1.13–1.53
12 5,493 447 1.17 1.03–1.33 5,376 441 1.18 1.04–1.34
13 6,023 419 1.00 5,899 409 1.00
14 2,760 178 0.93 0.79–1.10 2,692 173 0.93 0.78–1.10
≥ 15 2,006 119 0.86 0.70–1.04 1,958 117 0.86 0.71–1.05
Height relative to peers at age 10c
Taller 5,962 486 1.09 0.97–1.22 5,830 474 1.10 0.98–1.23
Same 8,964 675 1.00 8,770 658 1.00
Shorter 5,027 364 0.96 0.85–1.09 4,912 357 0.97 0.86–1.10
Weight relative to peers at age 10c
Heavier 4,054 325 1.09 0.96–1.24 3,966 317 1.09 0.96–1.24
Same 9,162 676 1.00 8,960 660 1.00
Lighter 6,725 521 1.05 0.94–1.17 6,575 509 1.05 0.94–1.17
aFibroids status based on self-reported diagnosis at ≤ 35 years of age, excluding 89 women missing fibroid status or age at diagnosis or who reported childhood or adolescent ages at 
diagnosis (< 15 years). bEach age-adjusted model included participant’s age; each fully adjusted model included the following covariates: participant’s age and education, maternal 
age, firstborn status, and childhood family income.cn does not sum to total because of missing data.D’Aloisio et al.
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We found a consistent association of 
fibroids with three indicators of low socio-
economic status during childhood (low house-
hold education, food insecurity, and poverty). 
These factors may influence development 
of fibroids through changes in methylation 
patterns in childhood that persist and affect 
gene expression as adults. Plausibility of this 
hypothesis is based on animal and human data 
on early-life neglect or abuse. Different methy-
lation patterns within the hippocampus of 
adult rats were detected based on whether they 
received maternal care early in life (Weaver 
et al. 2004). In a small sample of adult men 
who committed suicide, methylation patterns 
in similar genes in the hippocampus varied 
based on whether they were abused during 
childhood (McGowan et al. 2009). Whether 
being exposed to low socioeconomic condi-
tions during childhood can affect methylation 
patterns in genes relevant to fibroid pathogen-
esis needs further investigation.
We also found a strong association with 
fibroids for being born at least 1 month before 
mother’s due date. A weak association with 
low birth weight was no longer present after 
excluding women who were born at least 
1 month early. Because levels of estrogen and 
progesterone rise throughout pregnancy, one 
hypothesis is that women who are born early 
are deprived of the estrogen needed for full 
differentiation of their reproductive system 
(Trotter and Pohlandt 2000). Our analyses 
were limited by having only 60% of women 
who reported gestational age at birth. Missing 
data may be related to the true values of ges-
tational age or other birth-related variables, 
but results were similar when we repeated the 
analyses assuming women missing gestational 
age data were not born ≥ 2 weeks early (data 
not shown).
Selection bias is a potential limitation for 
other exposures as well, given that the propor-
tion of missing values was as high as 20%. 
There were slight differences in the proportion 
with fibroids based on whether exposures were 
missing, with generally more women reporting 
fibroids among those with missing responses. 
Based on the assumption that women with 
missing data for rare exposures (preeclampsia, 
pregnancy-related hypertension, soy formula, 
DES use, prepregnancy diabetes, and gesta-
tional diabetes) were likely to be unexposed, 
we repeated analyses in which we considered 
women with missing values for these factors as 
unexposed. However, changes in RR estimates 
were minimal (data not shown).
There is also the potential for misclassifi-
cation of exposures given that women were 
reporting exposures during infancy and related 
to their mother’s pregnancy. However, women 
were provided phone cards to encourage them 
to ask these questions directly of their moth-
ers, and we excluded older women (> 59 years) 
who would be less likely to have living moth-
ers to ask about these exposures. In addition, 
response categories for many of the exposures 
included options of “definite” and “proba-
ble” that allowed for uncertainty in report-
ing. Associations with fibroids were generally 
consistent for definite and probable exposure, 
except associations with in utero DES exposure 
and maternal gestational diabetes, for which 
associations were much stronger with report-
ing probable exposure. Because none of these 
exposures is known to be related to fibroids, 
exposure misclassification would likely be 
nondifferential, which would generally result 
in RR estimates biased toward the null.
Our assessment of fibroid diagnoses was 
based exclusively on self-report. However, 
because fibroid incidence increases strongly 
with age, we only considered diagnoses by 35 
years of age to reduce misclassification in the 
noncase group. Our estimated risk of 8% for 
early diagnosis of fibroids was similar to the 
risk of 11% for self-reported fibroids by 35 
years of age in white women (35–49 years of 
age) from the NIEHS Uterine Fibroid Study 
(Baird DD, unpublished observations). We 
also reported a substantially greater propor-
tion of women with early diagnosis of fibroids 
having hysterectomies compared with women 
without early diagnosis, which suggests that 
many of the women with fibroid diagnoses 
included in our case definition had fibroid-
related morbidity. However, we do not have 
information on fibroid-related symptoms at 
time of diagnosis. We also excluded older 
women from our analyses because of possi-
ble secular differences in use of ultrasounds 
for fibroid diagnoses. Because studied factors 
may also be related to fibroids diagnosed later 
in life, including women with fibroids diag-
nosed after 35 years of age as noncases may 
have resulted in an underestimation of RRs. 
However, repeating our analyses after exclu-
sion of women with later diagnoses of fibroids 
(> 35 years) from the noncase group did not 
affect RR estimates with early diagnosis of 
fibroids for four of our main findings (mater-
nal prepregnancy diabetes, soy formula, low 
childhood socioeconomic status, and being 
born at least 1 month early (data not shown). 
Strengths of this study include a large 
sample size, which allowed us to examine asso-
ciations with rare intrauterine and early-life 
exposures. We adjusted for factors that may 
affect recall of exposures, including partici-
pant’s age and education. In addition, despite 
the potential for misclassification bias from 
self-reported exposure information and fibroid 
diagnoses, we observed expected associations 
between specific factors, including a positive 
association between early age at menarche and 
fibroids and an increased reporting of mater-
nal preeclampsia among firstborn women and 
those from a multiple birth (data not shown).
Conclusions
Our study suggests that being fed with soy 
formula during infancy, having a mother 
with prepregnancy diabetes, being born at 
least 1 month early, and growing up with 
low socioeconomic conditions may increase 
the development of fibroids in early adult-
hood. This is the first study to explore these 
early-life and childhood factors in relation to 
the risk of fibroids. There are plausible bio-
logical mechanisms by which these factors 
could affect uterine physiology later in life 
and thus increase risk of fibroid development. 
Replication of findings in other populations 
including higher risk groups such as African 
Americans is needed.
co r r e c t i o n
In Table 1, the values for body mass index 
were incorrect in the manuscript originally 
published online. They have been corrected 
here.
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